| 1 |
Abiraterone and Increased Survival in Metastatic Prostate Cancer
Johann Sebastian De Bono et al. · New England Journal of Medicine
Open access |
25 May 2011 |
4,448 |
| 2 |
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al. · European Urology
Open access |
31 Aug 2016 |
3,282 |
| 3 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Nicholas David James et al. · The Lancet
Open access |
21 Dec 2015 |
1,985 |
| 4 |
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
John P. Neoptolemos et al. · The Lancet
Open access |
24 Jan 2017 |
1,953 |
| 5 |
The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
Joanne Haviland, John R. Owen, John A. Dewar et al. · The Lancet Oncology
Open access |
18 Sep 2013 |
1,479 |
| 6 |
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
Philip A Cornford, Joaquim Bellmunt, M. Bolla et al. · European Urology
|
9 Sep 2016 |
1,461 |
| 7 |
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Karim S. Fizazi, Howard I. Scher, Arturo Molina et al. · The Lancet Oncology
|
17 Sep 2012 |
1,402 |
| 8 |
The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients
Heinz Ludwig, Simon Van Belle, Peter J. Barrett-Lee et al. · European Journal of Cancer
|
17 Sep 2004 |
939 |
| 9 |
Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial
R.D. James, Rob Glynne‐Jones, Helen Margaret Meadows et al. · The Lancet Oncology
Open access |
9 Apr 2013 |
738 |
| 10 |
Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
Dragan Ilić, Mia Djulbegovic, Jae Hung Jung et al. · BMJ
ReviewOpen access |
5 Sep 2018 |
649 |
| 11 |
Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression
Aled Clayton, John Paul Mitchell, Jacquelyn Court et al. · The Journal of Immunology
Open access |
Jun 2008 |
585 |
| 12 |
Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial
Padraig Richard Warde, Malcolm Mason, Keyue Ding et al. · The Lancet
Open access |
3 Nov 2011 |
584 |
| 13 |
Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004–2007
Sarah Walters et al. · Thorax
Open access |
11 Feb 2013 |
579 |
| 14 |
Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial
Michel Seymour, Tim Maughan, Jonathan A. Ledermann et al. · The Lancet
|
Jul 2007 |
569 |
| 15 |
Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry
Aled Clayton, Jacquelyn Court, Hossein Navabi et al. · Journal of Immunological Methods
|
2001 |
557 |
| 16 |
The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review
Nicola Fossati et al. · European Urology
ReviewOpen access |
24 Jan 2017 |
545 |
| 17 |
Human Tumor-Derived Exosomes Selectively Impair Lymphocyte Responses to Interleukin-2
Aled Clayton, John Paul Mitchell, Jacquelyn Court et al. · Cancer Research
Open access |
Aug 2007 |
518 |
| 18 |
Is There Evidence That Palliative Care Teams Alter End-of-Life Experiences of Patients and Their Caregivers?
Irene J Higginson, Ilora Gillian Finlay, Danielle M. Goodwin et al. · Journal of Pain and Symptom Management
Open access |
Feb 2003 |
508 |
| 19 |
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Karim S. Fizazi et al. · New England Journal of Medicine
Open access |
16 Feb 2023 |
447 |
| 20 |
Survival with Newly Diagnosed Metastatic Prostate Cancer in the “Docetaxel Era”: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)
Nicholas David James, Melissa Ruth Spears, Noel William Clarke et al. · European Urology
Open access |
7 Oct 2014 |
440 |
| 21 |
Palliation of Metastatic Bone Pain: Single Fraction versus Multifraction Radiotherapy – A Systematic Review of Randomised Trials
Wai Man Sze, Michael D. Shelley, I. W. HELD et al. · Clinical Oncology
Review |
Sep 2003 |
436 |
| 22 |
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial
Michel Seymour, Lindsay C Thompson, Harpreet Singh Wasan et al. · The Lancet
Open access |
May 2011 |
421 |
| 23 |
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data
Claire Louise Vale, Sarah Burdett, Larysa H. M. Rydzewska et al. · The Lancet Oncology
ReviewOpen access |
21 Dec 2015 |
408 |
| 24 |
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid et al. · Journal of Clinical Oncology
Open access |
16 Dec 2019 |
397 |
| 25 |
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol
Gerhardt Attard et al. · The Lancet
ReviewOpen access173 authors |
23 Dec 2021 |
387 |
| 26 |
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial
T. Crosby, Chris N Hurt, Stephen J. Falk et al. · The Lancet Oncology
Open access |
25 Apr 2013 |
387 |
| 27 |
Effective dose from cone beam CT examinations in dentistry
J A ROBERTS, Nicholas A. Drage, Jonathan S. Davies et al. · British Journal of Radiology
|
18 Dec 2008 |
381 |
| 28 |
Radioisotopes for the palliation of metastatic bone cancer: a systematic review
Ilora Gillian Finlay, Malcolm David Mason, Mike Shelley · The Lancet Oncology
Review |
30 May 2005 |
372 |
| 29 |
Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial
Nicholas C. Turner et al. · The Lancet Oncology
Open access |
10 Sep 2020 |
369 |
| 30 |
Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial
Somnath Mukherjee, Chris N Hurt, John A. Bridgewater et al. · The Lancet Oncology
Open access |
6 Mar 2013 |
358 |
| 31 |
Do Hospital-Based Palliative Teams Improve Care for Patients or Families at the End of Life?
Irene J Higginson, Ilora Gillian Finlay, Danielle M. Goodwin et al. · Journal of Pain and Symptom Management
Open access |
Feb 2002 |
346 |
| 32 |
Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials
Michael D. Shelley, Timothy J Wilt, J.B. Court et al. · British Journal of Urology
|
20 Feb 2004 |
345 |
| 33 |
Adhesion and signaling by B cell‐derived exosomes: the role of integrins
Aled Clayton, Atilla Turkes, Sharon Dewitt et al. · The FASEB Journal
|
Apr 2004 |
343 |
| 34 |
Antigen‐presenting cell exosomes are protected from complement‐mediated lysis by expression of CD55 and CD59
Aled Clayton, Claire L. Harris, Jacquelyn Court et al. · European Journal of Immunology
Open access |
31 Jan 2003 |
341 |
| 35 |
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome
H Anderson, Penelope Hopwood, RJ Stephens et al. · British Journal of Cancer
Open access |
Aug 2000 |
341 |
| 36 |
Effectiveness of multifaceted educational programme to reduce antibiotic dispensing in primary care: practice based randomised controlled trial
Christopher Butler, Sharon Anne Simpson, Frank Dunstan et al. · BMJ
Open access |
2 Feb 2012 |
331 |
| 37 |
Can urinary exosomes act as treatment response markers in prostate cancer?
Paul Mitchell, Joanne Louise Welton, John Nicholas Staffurth et al. · Journal of Translational Medicine
Open access |
12 Jan 2009 |
314 |
| 38 |
A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
Michael D. Shelley, Howard Kynaston, J.B. Court et al. · British Journal of Urology
Review |
Aug 2001 |
314 |
| 39 |
Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
Attard, Gerhardt et al. · BORIS (University Library Bern)
ReviewOpen access |
29 Jan 2022 |
311 |
| 40 |
A scored form of the Bristol Female Lower Urinary Tract Symptoms questionnaire: Data from a randomized controlled trial of surgery for women with stress incontinence
SARA T. BROOKES, Jenny Donovan, Melissa Wright et al. · American Journal of Obstetrics and Gynecology
|
Jul 2004 |
310 |
| 41 |
Reporting of Short-Term Clinical Outcomes After Esophagectomy
Natalie Blencowe, Sean Strong, Angus McNair et al. · Annals of Surgery
|
7 Mar 2012 |
297 |
| 42 |
Multidisciplinary team management is associated with improved outcomes after surgery for esophageal cancer
Michael Stephens, Wyn Griffith Lewis, Alison E. Brewster et al. · Diseases of the Esophagus
Open access |
24 May 2006 |
278 |
| 43 |
PATHOS: a phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV) positive oropharyngeal cancer
Waheeda Owadally, Chris N Hurt, Hayley Timmins et al. · BMC Cancer
Open access |
26 Aug 2015 |
275 |
| 44 |
Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection
Nathalie Chaput, Noël E.C. Schartz, Fabrice André et al. · The Journal of Immunology
|
Feb 2004 |
266 |
| 45 |
Undescribed toxin in pseudomembranous colitis.
H Elliott Larson, John V. Parry, A B Price et al. · BMJ
Open access |
14 May 1977 |
258 |
| 46 |
Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer
Satish Kumar, Mike Shelley, Craig Harrison et al. · Cochrane Database of Systematic Reviews
Open access |
18 Oct 2006 |
258 |
| 47 |
A randomized, dose–response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer
Sten F. Nilsson, Peter M. Strang, A. Aksnes et al. · European Journal of Cancer
Open access |
16 Feb 2012 |
249 |
| 48 |
Breast cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK, 2000-2007: a population-based study
The ICBP Module 1 Working Group20 et al. · British Journal of Cancer
Open access |
28 Feb 2013 |
249 |
| 49 |
4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial
Peter Hoskin, Amy A. Kirkwood, Bilyana Popova et al. · The Lancet Oncology
|
23 Feb 2014 |
248 |
| 50 |
A Review of the Clinical Evidence for Intensity-modulated Radiotherapy
John Nicholas Staffurth · Clinical Oncology
Open access |
3 Aug 2010 |
235 |